1 Papers
12 Citations
Ping Ling is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Mitogen-activated protein kinase & MAP kinase kinase kinase. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Inhibitors of unactivated p38 MAP kinase.
James L. Bullington,Dennis C. Argentieri,Kristin M. Averill,Demetrius Carter,Druie Cavender,Bohumila Fahmy,Xiaodong Fan,Hall Daniel A,Geoffrey R. Heintzelman,Paul F. Jackson,Wai Ping Leung,Xun Li,Ping Ling,Gilbert C. Olini,Thomas Razler,Michael Reuman,Kenneth C. Rupert,Ronald K. Russell,John Siekierka,Scott A. Wadsworth,Russell Wolff,Bangping Xiang,Yue Mei Zhang +22 more
TL;DR: A novel series of pyridinylimidazole-based compounds are developed, which potently inhibit the p38 pathway by binding to unactivated p38 kinase and only weakly inhibiting activated p38 Kinase activity in vitro.
14